HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Albertus M. Scheule Friedrich S. Eckstein Markus K. Heinemann Gerhard Ziemer Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scheule, A. M. Articles by Ziemer, G. Search for Related Content PubMed PubMed Citation Articles by Scheule, A. M. Articles by Ziemer, G.

J Thorac Cardiovasc Surg 1998;115:883-889
© 1998 Mosby, Inc.

SURGERY FOR CONGENITAL HEART DISEASE

Fibrin sealant, aprotinin, and immune response in children undergoing operations for congenital heart disease

From the Department of Surgery, Division of Thoracic, Cardiac and Vascular Surgery, Eberhard-Karls-University, Tuebingen, Germany.

Received for publication May 15, 1997. Revisions requested August 12, 1997; revisions received Sept. 26, 1997. Accepted for publication Sept. 29, 1997. Address for reprints: Prof. Dr. med. G. Ziemer, Division of Thoracic, Cardiac and Vascular Surgery, Eberhard-Karls-University, Tuebingen, Hoppe-Seyler-Strasse 3, D-72076 Tuebingen, Germany.

Objective: Most commercially available fibrin sealants contain aprotinin in doses of 1500 kallikrein inactivator units per milliliter. They are used in many operative disciplines. An elevated risk of hypersensitivity reactions exists at reexposure to aprotinin. Our aim was to examine the immunogenic potency of aprotinin as a fibrin sealant content.
Methods: We investigated 49 children with operatively treated congenital heart disease. All patients received aprotinin only topically as contained in fibrin sealant. Serum samples were drawn preoperatively, 1 week, 2 weeks, 6 weeks, and approximately 1 year after operation. They were analyzed for aprotinin-specific immunoglobulin G antibodies with a standard enzyme-linked immunosorbent assay and a fluorescence enzyme immunoassay for aprotinin-specific immunoglobulin E antibodies.
Results: At 1 week, 2 weeks, 6 weeks, and 1 year, we found prevalences of 8% (2 of 26), 8% (2 of 24), 6% (3 of 49), and 0% for aprotinin-specific Immunoglobulin E, and for aprotinin-specific immunoglobulin G 8% (2 of 26), 17% (4 of 24), 39% (19 of 49), and 12% (5 of 41). The doses of aprotinin given did not differ significantly in antibody-negative and antibody-positive patients; no significant factors could predict the immune response.
Conclusions: Our findings show the existence of a subgroup of patients who had aprotinin-specific antibodies develop after topical aprotinin application. Any use of aprotinin must be carefully documented. If aprotinin use is planned in patients who previously underwent a surgical procedure, preexposure to aprotinin in any form must be sought to avoid unexpected anaphylactic reactions. The necessity itself and alternatives for aprotinin as a stabilizing agent in fibrin sealants merit consideration. (J Thorac Cardiovasc Surg 1998;115:883-9)

This article has been cited by other articles:

				H. Goerler, P. Oppelt, U. Abel, and A. Haverich Safety of the use of Tissucol(R) Duo S in cardiovascular surgery: retrospective analysis of 2149 patients after coronary artery bypass grafting Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 560 - 566. [Abstract] [Full Text] [PDF]

				W. Beierlein, A. M. Scheule, W. Dietrich, and G. Ziemer Forty Years of Clinical Aprotinin Use: A Review of 124 Hypersensitivity Reactions Ann. Thorac. Surg., February 1, 2005; 79(2): 741 - 748. [Abstract] [Full Text] [PDF]

				M. Schwartz, J. Madariaga, R. Hirose, T. R. Shaver, L. Sher, R. Chari, J. O. Colonna II, N. Heaton, D. Mirza, R. Adams, et al. Comparison of a New Fibrin Sealant With Standard Topical Hemostatic Agents Arch Surg, November 1, 2004; 139(11): 1148 - 1154. [Abstract] [Full Text] [PDF]

				R. D. B. Jaquiss, N. S. Ghanayem, M. C. Zacharisen, K. A. Mussatto, J. S. Tweddell, and S. B. Litwin Safety of Aprotinin Use and Re-Use in Pediatric Cardiothoracic Surgery Circulation, September 24, 2002; 106(12_suppl_1): I-90 - I-94. [Abstract] [Full Text] [PDF]

				L. A. Gramlich and S. D. Barnes Aprotinin Use in Pediatric Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2001; 5(1): 117 - 121. [Abstract] [PDF]

				W. Beierlein, A. M. Scheule, and G. Ziemer Anaphylactic aprotinin reaction Ann. Thorac. Surg., April 1, 2000; 69(4): 1298 - 1298. [Full Text] [PDF]

				A. M. Scheule, W. Beierlein, S. Arnold, F. S. Eckstein, J. M. Albes, and G. Ziemer The Significance of Preformed Aprotinin-Specific Antibodies in Cardiosurgical Patients Anesth. Analg., February 1, 2000; 90(2): 262 - 262. [Abstract] [Full Text] [PDF]

				E. N. Probst, U. Grzyska, M. Westphal, and H. Zeumer Preoperative Embolization of Intracranial Meningiomas with a Fibrin Glue Preparation AJNR Am. J. Neuroradiol., October 1, 1999; 20(9): 1695 - 1702. [Abstract] [Full Text]

				A. M. Scheule, W. Beierlein, H. P. Wendel, M. J. Jurmann, F. S. Eckstein, and G. Ziemer APROTININ IN FIBRIN TISSUE ADHESIVES INDUCES SPECIFIC ANTIBODY RESPONSE AND INCREASES ANTIBODY RESPONSE OF HIGH-DOSE INTRAVENOUS APPLICATION J. Thorac. Cardiovasc. Surg., August 1, 1999; 118(2): 348 - 353. [Abstract] [Full Text] [PDF]